Orthogon Biosciences Targets Viral Capsid Protein VP1 for Next-Generation Antiviral Therapy

Orthogon Biosciences is advancing a novel antiviral strategy that directly targets the viral capsid protein VP1, a critical component in the life cycle of certain enteroviruses. By focusing on this structural protein, the company aims to disrupt viral replication at its source — inside infected cells — offering a potential modern approach to treating infections that currently lack effective therapies.

Understanding the Role of VP1 in Viral Infection

The VP1 protein is a key part of the icosahedral capsid found in non-enveloped viruses such as poliovirus, coxsackievirus, and enterovirus D68 (EV-D68). These viruses rely on VP1 to attach to host cell receptors, facilitate entry, and protect their genetic material during transmission. Given that VP1 is exposed on the viral surface and essential for infectivity, it has become an attractive target for antiviral intervention.

Unlike some antivirals that act after viral entry or during replication, Orthogon’s lead candidate is designed to bind to VP1 and prevent the conformational changes necessary for the virus to release its RNA into the host cell. This mechanism blocks infection at an early stage, potentially reducing viral load before widespread cellular damage occurs.

Mechanism of Action: Blocking Viral Uncoating

Orthogon’s therapeutic approach centers on inhibiting the “uncoating” process — the step where the virus sheds its capsid to release its genome into the host cytoplasm. By stabilizing the VP1 protein or locking it in a non-infectious conformation, the drug candidate prevents this critical transition.

Virus attaches to cell → VP1 mediates entry → Conformational change triggers RNA release → Infection established 

Orthogon’s molecule intervenes at the conformational change step, effectively trapping the virus in a pre-entry state. This mechanism is particularly promising because it acts extracellularly or at the point of entry, minimizing intracellular off-target effects.

Target Viruses and Clinical Relevance

The lead asset is being developed primarily against enteroviruses, a genus of Picornaviridae that includes over 100 serotypes capable of causing diseases ranging from mild respiratory illness to severe neurological conditions like acute flaccid myelitis (AFM), meningitis, and myocarditis.

Enterovirus D68 has garnered increased attention in recent years due to biennial spikes in AFM cases among children in the United States and other countries. Despite outbreaks occurring roughly every two years since 2014, no FDA-approved antiviral exists specifically for EV-D68 or related neurotropic enteroviruses.

By targeting a highly conserved region of VP1 across multiple enterovirus strains, Orthogon’s approach may offer broad-spectrum activity — a significant advantage over serotype-specific antibodies or vaccines that require frequent updates.

Preclinical Progress and Research Backing

Orthogon Biosciences has demonstrated proof-of-concept in preclinical models showing that its lead compound reduces viral titers in cell cultures infected with EV-D68 and coxsackievirus B3 (CVB3). Studies indicate that the compound binds directly to VP1 with high affinity, preventing the structural rearrangements needed for viral entry.

These findings align with earlier academic research identifying VP1 as a viable druggable target. For example, studies published in Nature Microbiology and PLOS Pathogens have shown that small molecules binding to the VP1 hydrophobic pocket can inhibit a broad range of picornaviruses by stabilizing the capsid.

Orthogon is building on this scientific foundation through medicinal chemistry optimization to improve potency, pharmacokinetics, and safety profiles. The company has not yet disclosed clinical trial timelines but indicates that IND-enabling studies are underway.

Advantages Over Existing Antiviral Strategies

Current antiviral options for enteroviruses are limited. Pleconaril, an earlier VP1-targeting compound, showed promise in clinical trials for respiratory infections but failed to gain FDA approval due to pharmacokinetic issues and concerns about drug interactions.

Orthogon’s next-generation design aims to overcome these limitations by:

• Improving metabolic stability to reduce dosing frequency
• Minimizing cytochrome P450 enzyme interactions
• Enhancing bioavailability for systemic or topical delivery
• Maintaining activity against resistant viral mutants

because the mechanism acts outside the genome replication machinery, there may be a lower barrier to resistance compared to nucleoside analogs or protease inhibitors, which exert strong selective pressure on viral polymerase.

Future Outlook and Development Pathway

Orthogon Biosciences is positioning its VP1-targeted therapy as a potential first-in-class antiviral for enteroviral infections with significant unmet medical need. The company plans to pursue initial clinical development in populations at high risk for severe disease, such as immunocompromised children or those with underlying cardiopulmonary conditions.

Success in early trials could open pathways for broader use, including prophylactic applications during outbreak seasons or stockpiling for pandemic preparedness. Given the seasonal and unpredictable nature of enterovirus outbreaks, having a ready-to-deploy antiviral could significantly improve public health responses.

Although the therapeutic is still in preclinical stages, the rationale is strong: targeting a conserved, structurally accessible protein essential for infectivity offers a logical and scientifically grounded path forward. As research into viral entry mechanisms advances, capsid-directed therapeutics like Orthogon’s may represent a growing class of antivirals effective against otherwise challenging pathogens.

Frequently Asked Questions

What is VP1, and why is it a good drug target?

VP1 is the major structural protein forming the outer surface of non-enveloped viruses like enteroviruses. It mediates host cell attachment and entry and is essential for infectivity. Because it is exposed on the virion surface and highly conserved across strains, VP1 is accessible to small molecules or biologics and less prone to rapid mutation without losing function.

How does Orthogon’s antiviral differ from vaccines or monoclonal antibodies?

Vaccines prevent infection by eliciting immune memory, while monoclonal antibodies provide passive immunity but can be costly and strain-specific. Orthogon’s small molecule acts directly to block viral entry, offering potential therapeutic use after exposure and broader coverage across enterovirus types due to targeting a conserved region.

Is there a cure for enterovirus infections currently?

No. Treatment for enteroviral infections is primarily supportive — managing symptoms like fever, respiratory distress, or neurological complications. No antiviral is FDA-approved specifically for enteroviruses, making novel candidates like Orthogon’s critically significant.

When might this therapy be available to patients?

Orthogon’s lead candidate is currently in preclinical development. Assuming successful IND-enabling studies, clinical trials could begin in the next 2–3 years, with potential approval timelines dependent on trial outcomes and regulatory pathways.

Could this approach work against other viruses?

Yes, the strategy of targeting viral capsid proteins has been explored for other picornaviruses (e.g., rhinovirus, poliovirus) and even some non-picornaviruses with accessible capsid interfaces. Orthogon’s platform may have broader applications beyond enteroviruses.